Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

  • Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74

  • Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors1,2,3

  • Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio

Basel, March 30, 2021 — …

/by

Novartis statement on comment in Swiss media

Basel, March 23, 2021 — On Saturday, March 6, 2021, SonntagsBlick published an interview with Novartis Chairman Joerg Reinhardt, Ph.D., in connection with the 25th anniversary of the founding of the company. In the interview, Mr. Reinhardt was asked about the company’s $678 million settlement last year with the United States Government, which resolved claims that during the time period from 2002 to 2011, Novartis used certain promotional programs as a way improperly to induce doctors to prescribe Novartis products, in violation of US anti-kickback law.

In …

/by

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

  • Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer1
  • VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021
  • Novartis is committed to reimagining prostate cancer through targeted radioligand therapy with …
/by

Novartis joins pharma-wide effort to meet global demand for COVID-19 vaccines

With the approval of several COVID-19 vaccines, there is growing hope that the world might find a way to end the COVID-19 pandemic. Challenges remain – including a bottleneck in manufacturing that is making it hard for companies to meet demand. 

In response, companies across the pharmaceutical industry are collaborating in new ways, including working together to manufacture vaccines as rapidly as possible.

Novartis, for instance, no longer has a vaccine business, but it does have one of the largest and most diverse manufacturing operations in the industry. So we are …

/by

Novartis inaugurates innovative watershed project in India to increase water availability

The south bank of the Musi River in Hyderabad, India

Today, on World Water Day, Novartis inaugurated an integrated watershed development project to help address water scarcity in the Telangana region of India, one of the world’s most water-stressed countries.

Managed jointly with the …

/by

Novartis appoints Karen Hale as Chief Legal Officer

Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective May 15, 2021. Ms. Hale will be based in Basel, Switzerland and succeeds Shannon Klinger. Tom Kendris will continue as Chief Legal Officer ad interim until Ms. Hale joins.

Ms. Hale brings to Novartis over 20 years of deep, global legal and compliance experience in the pharmaceutical industry. She joins …

/by

Highlights from the Co-Creating Impact Summit 2020

The third annual Co-Creating Impact Summit in collaboration with Novartis’ Impact Valuation Advisory Council – chaired by John Elkington – brought together internal and external thought leaders in the area of ESG, sustainability and impact valuation to discuss and debate on the current status, future perspectives and ways Novartis could be best prepared for the future. 

The hugely successful event with over 1’100 registrations reflected on the most pressing topics around Investors and Sustainability, Climate and Health, the Future of Integrated Reporting, the Role of Governments, and …

/by

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment

  • Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse events
  • Real-world data indicate older children (aged ≥6 months) achieved clinically meaningful benefit with Zolgensma alone, after or in combination with another SMA therapy, with events consistent with the previously described safety profile
  • Zolgensma led to achievement of new milestones years after …
/by

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

  • Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments1

  • Canakinumab development program continues; two Phase III non-small cell lung cancer clinical trials are ongoing in first-line and adjuvant settings2,3 
  • The CANOPY clinical trial program is designed to help answer critical questions about the role …
/by

EPIS explores how COVID-19 is shaping the future of digital engagement within healthcare

The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient Innovation Summit (EPIS) explored the positive and negative aspects of digital engagement during the COVID-19 pandemic at EPIS 2020 and made recommendations on how patients can continue to benefit from digital engagement in future.

The positive impact of these digital tools has been that they help patients …

/by